Can a skin cancer drug reboot chemo for tough breast tumors?
NCT ID NCT04664829
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested whether the drug bexarotene (Targretin) could make chemotherapy-resistant triple-negative breast cancer cells sensitive to chemo again. Twelve women with metastatic, taxane-resistant breast cancer took bexarotene pills plus capecitabine (Xeloda) chemotherapy. The study looked at changes in tumor genes and proteins, and monitored side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bexarotene (Targretin) and capecitabine (Xeloda)
What this could lead to
If it works, this could point toward a way to make chemotherapy effective again for some people with hard-to-treat breast cancer.
What could go wrong
This is a very early, small Phase 1 trial with only 12 people. It is designed mainly to check safety and biological changes, not to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Singapore
Singapore, 168583, Singapore